Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

In today’s episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted an in-depth discussion with Jonathan W. Lee, MD, MSc, on the evolving therapeutic landscape for EGFR-mutant and HER2-positive non–small cell lung cancer (NSCLC). Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Lee is the chief oncology/hematology fellow at Weill Cornell Medicine in New York, New York.

Their conversation began with a focus on how emerging clinical evidence is reshaping treatment approaches for patients with locally advanced or metastatic NSCLC harboring EGFR mutations. The discussion explored first-line decision-making when selecting between osimertinib (Tagrisso), osimertinib plus chemotherapy, or amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze), as well as strategies for treating patients with nonclassical EGFR mutations outside of exon 19 deletions and exon 21 L858R alterations.

Dr Levy and Dr Lee also reviewed advances in targeted therapy for patients with actionable gene fusions, including ALK, ROS1, and RET. They discussed the clinical utility of later-generation TKIs such as lorlatinib (Lorbrena) on sequencing decisions for patients with ALK rearrangements and highlighted the complexities of treatment selection in settings where multiple TKIs are approved without head-to-head comparative data. The experts also addressed emerging oncogenic drivers that may serve as the basis for future therapeutic development in NSCLC.

The conversation further examined how the incorporation of immunotherapy into earlier disease stages has begun to shift standards of care for patients with resectable NSCLC. Topics included how prior exposure to perioperative immunotherapy may influence subsequent treatment decisions at recurrence or progression, and whether strategies used in advanced disease—such as combination immunotherapy regimens or biomarker-guided treatment selection—may eventually translate into earlier-stage contexts through ongoing or future clinical research.

This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding from AstraZeneca; however, content is produced and independently developed by OncLive.